Our Pipeline

We are collaborating with MJJ Biotech A/S, a wholly-owned subsidiary in Denmark, to develop new drugs targeting liver, kidney and central nervous system diseases. The following are the current R&D projects:


Rare CNS/vascular Disease

Preclinical


Rare Neurodegenerative diseases – partnered 

Preclinical


Age-related macular degeneration

Preclinical


Rare Chronic Kidney Disease

exploratory